ADX-63365
/ Addex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 23, 2011
Addex Pharmaceuticals 2010 Financial Results
(SA)
-
ADX63365, a preclinical mGluR5 PAM, is licensed to Merck as a potential treatment for schizophrenia and undisclosed indications; Addex is eligible for up to USD680 million in milestones plus royalties
Schizophrenia
1 to 1
Of
1
Go to page
1